[1andrew1]

This is an interesting observation.

Perhaps significantly, for a company that has suffered public relations problems, there is nobody on the senior executive team with communications as a core part of their responsibilities, a difference from rivals such as Pfizer or GlaxoSmithKline.

One insider said: “There is a general sense of the company being buffeted on the reputational issue and just not being able to get on top of it.”

In this week’s example, the company had wanted to release promptly the findings from its large US trial, aware they could help lay to rest damaging questions about its safety and benefits, but had neglected to agree the press release in advance with the independent monitoring board.

Few lessons seemed to have been learned from an early data release in November, which caused confusion and controversy when three separate efficacy levels were included. Only later did it emerge that one dosing regime had been due to an initial error and had not been tested on people over the age of 55.

https://www.ft.com/content/7df5e368-...3-5b2e623ce708